MASSDEVICE ON CALL — The medical device world will be watching intently this weekend as Medtronic (NYSE:MDT) releases data for the 1st time from a failed clinical trial of its Symplicity renal denervation device.
Hypertension
Hypertension: Cordis lands Euro approval for Renlane renal denervation
Medtronic posts a Q3 profit slide on renal denervation writedown, narrows outlook
Hypertension: ReCor charges ahead with ultrasound renal denervation
Analysts warn of deeper impact of Medtronic’s renal denervation miss | MassDevice.com On Call
MASSDEVICE ON CALL — Medtech titan Medtronic (NYSE:MDT) took a risk when it bet nearly $1 billion on renal denervation pioneer Ardian years before its flagship device was slated to hit the U.S. market, and the recent foofaraw over the company’s missed clinical trial may have a cooling effect on other device companies, analysts warned.
Covidien bails on renal denervation
In defense of renal denervation: Managing expectations in the aftermath of Symplicity HTN-3
It’s not so Symple: the Rise (and Fall?) of Renal Denervation
Renal denervation ‘highly unlikely’ for hypertension, says Medtronic study insider
The future of renal denervation in treatment of hypertension is shaky at best, according to 1 of the principal investigators involved with Medtronic’s disappointing clinical trial.